Antiretroviral Therapy and Bone Health

1. Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol 2015;4(3):388-95.10.5527/wjn.v4.i3.388449193026167463Search in Google Scholar

2. Borissova AM, Rashkov R, Boyanov M et al. Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older. Arch Osteoporos 2011;6:189-95.10.1007/s11657-011-0064-x22886105Search in Google Scholar

3. Bruera D, Luna N, David DO et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17(13):1917-23.10.1097/00002030-200309050-0001012960824Search in Google Scholar

4. Cazanave C, Dupon M, Lavignolle-Aurillac V et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008;22(3):395-402.10.1097/QAD.0b013e3282f423dd18195566Search in Google Scholar

5. Chitu-Tisu CE, Barbu EC, Lazar M et al. Body composition in HIV-infected patients receiving highly active antiretroviral therapy. Acta Clin Belg 2017;72(1):55-62.10.1080/17843286.2016.124042627724840Search in Google Scholar

6. Chitu-Tisu CE, Barbu EC, Lazar M et al. Low bone mineral density and associated risk factors in HIV-infected patients. Germs 2016;6(2):50-9.10.11599/germs.2016.1089495616127482514Search in Google Scholar

7. Danjuma MI, Mohamad-Fadzillah NH, Khoo S. An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database). Int J STD AIDS 2014;25(4):273-9.10.1177/095646241350474724067251Search in Google Scholar

8. Deya-Martinez A, Fortuny C, Soler-Palacin P et al. Cystatin C: a marker for inflammation and renal function among HIV-infected children and adolescents. Pediatr Infect Dis J 2016;35(2):196-200.10.1097/INF.000000000000096026479972Search in Google Scholar

9. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleo-side reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23(7):817-24.10.1097/QAD.0b013e328328f78919363330Search in Google Scholar

10. Ezinga M, Wetzels JF, Bosch ME et al. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther 2014;19(8):765-71.10.3851/IMP276124584104Search in Google Scholar

11. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40(8):1194-8.10.1086/428840Search in Google Scholar

12. Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 2017. doi: 10.1007/s00198-017-4305-8.10.1007/s00198-017-4305-8Open DOISearch in Google Scholar

13. Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS 2016;11(3):326-32.10.1097/COH.0000000000000248Search in Google Scholar

14. Grigsby IF, Pham L, Mansky LM et al. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010;6:41-7.10.2147/TCRM.S8836Search in Google Scholar

15. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011;57(5):773-80.10.1053/j.ajkd.2011.01.022Search in Google Scholar

16. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes 2015;22(6):446-51.10.1097/MED.0000000000000200Search in Google Scholar

17. Hojs R, Bevc S, Ekart R et al. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol 2008;70(1):10-7.10.5414/CNP70010Search in Google Scholar

18. Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract 2013;19(1):120-8.10.4158/EP12059.RASearch in Google Scholar

19. International Society for Clinical Densitometry (ISCD). 2017. Available from: https://www.iscd.org/official-positions/official-positions/. [Accessed 22 November 2017].Search in Google Scholar

20. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991;20(4):256-72.10.1016/0049-0172(91)90021-QSearch in Google Scholar

21. Kirilov G. Laboratory diagnosis of parathyroid gland diseases and bone mineral metabolism. In: Paradigm, editor. Hormonal and Functional Diagnosis of Endocrine Diseases; 2012.Search in Google Scholar

22. Kohlmeier L, Gasner C, Bachrach LK, Marcus R. The bone mineral status of patients with Marfan syndrome. J Bone Miner Res 1995;10(10):1550-5.10.1002/jbmr.56501010178686512Search in Google Scholar

23. Lucas K, Behrens BA, Nolte I et al. Comparative investigation of bone mineral density using CT and DEXA in a canine femoral model. J Orthop Res 2017. doi: 10.1002/jor.23574.10.1002/jor.2357428387962Open DOISearch in Google Scholar

24. McComsey GA, Kitch D, Daar ES et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarateemtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011;203(12):1791-801.10.1093/infdis/jir188310051421606537Search in Google Scholar

25. McComsey GA, Tebas P, Shane E et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51(8):937-46.10.1086/656412310590320839968Search in Google Scholar

26. Moran CA, Weitzmann MN, Ofotokun I. Bone loss in HIV infection. Curr Treat Options Infect Dis 2017;9(1):52-67.10.1007/s40506-017-0109-9538845428413362Search in Google Scholar

27. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci 2006;1068:297-308.10.1196/annals.1346.057163483116831930Search in Google Scholar

28. Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep 2012;9(3):218-22.10.1007/s11904-012-0119-722581359Search in Google Scholar

29. Rosen CJ. The epidemiology and pathogenesis of osteoporosis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A et al. Endotext. South Dartmouth (MA): MDText. com, Inc.; 2000.Search in Google Scholar

30. Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 2011;64(12):1042-50.10.1136/jcp.2010.07784221896577Search in Google Scholar

31. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 2013;62(3):595-603.10.1053/j.ajkd.2013.03.027375510023701892Search in Google Scholar

32. Streinu-Cercel A, Sandulescu O, Ceapraga G, et al. Prevalence of osteo-renal impairment in the Romanian HIV cohort. BMC Infect Dis 2016;16 Suppl 1:93.10.1186/s12879-016-1397-2489625227169468Search in Google Scholar

33. Van Dijk FS. Genetics of osteoporosis in children. Endocr Dev 2015;28:196-209.10.1159/00038104626138843Search in Google Scholar

34. Wasserman P, Rubin DS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS 2010;24(4):223-7.10.1089/apc.2009.024120377437Search in Google Scholar

35. Welz T, Childs K, Ibrahim F et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. Aids 2010;24(12):1923-8.10.1097/QAD.0b013e32833c328120588161Search in Google Scholar

36. Woodward CL, Hall AM, Williams IG et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10(8):482-7.10.1111/j.1468-1293.2009.00716.x19459988Search in Google Scholar

37. World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level 2007. Available from: http://www.who.int/chp/topics/Osteoporosis.pdf. [Accessed 22 November 2017].Search in Google Scholar

38. Yancheva N. Complications of antiretroviral therapy in HIV-infected patients. Vitamin D deficiency. PhD Thesis.Search in Google Scholar

39. Yancheva N, Nikolova M, Alexandrova M et al. Deficiency of vitamin D in HIV infected patients and its effect on some of the immunological parameters. World J AIDS 2015;5(3):182-8.10.4236/wja.2015.53021Search in Google Scholar

40. Yancheva N, Tchervenyakova T, Gabarska I, Elenkov I. De-ficiency of vitamin D in HIV infected patients and its effect on some of the biochemical parameters. Indian J Pharm Sci 2016;3(2):57-64.Search in Google Scholar